Corcept Q3 revenue $96.1M (+11% YoY); narrows 2021 guide to $365-375M

CORCEPT THERAPEUTICS INC

2021-Q3 EPS reported $0.63 revenue$267,156,000

GAAP diluted EPS $0.24 vs $0.17 YoY; non-GAAP diluted EPS $0.30 vs $0.24.
Cash and investments $495.2M, up from $471.6M at June 30; repurchased 1.2M shares in Q3.
Plans Phase 3 trial in recurrent platinum-resistant ovarian cancer in Q1 2022; updated OS data expected Q1 2022.
Phase 2 NASH data to be presented at AASLD Nov 12-15; Phase 1b dose-finding trial initiated.
Relacorilant NDA submission for Cushing's syndrome expected Q2 2023; GRACE and GRADIENT trials enrolling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.